Cleavage of SNAP25 and its shorter versions by the protease domain of serotype a botulinum neurotoxin

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Mizanur, Rahman M ^a   Stafford, Robert G ^a   Ahmed, S Ashraf ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOVINE SERUM ALBUMIN; PROTEINASE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; CHLORIDE; DITHIOTHREITOL; PEPTIDE FRAGMENT; SNAP25 PROTEIN, HUMAN; SODIUM CHLORIDE; ZINC CHLORIDE; ZINC DERIVATIVE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; MOLECULAR DYNAMICS; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN FUNCTION; SEROTYPE; STEADY STATE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME SPECIFICITY; HUMAN; KINETICS; PROTEIN DEGRADATION;

BOTULINUM TOXINS, TYPE A; CHLORIDES; DITHIOTHREITOL; HUMANS; KINETICS; PEPTIDE FRAGMENTS; PROTEOLYSIS; SERUM ALBUMIN, BOVINE; SODIUM CHLORIDE; SUBSTRATE SPECIFICITY; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; ZINC COMPOUNDS;

EID: 84899747781     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095188     Document Type: Article

References (59)

1. Borio L, Frank D, Mani V, Chiriboga C, Pollanen M, et al. (2001) Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA 286: 2554-2559. (Pubitemid 33096806)
2. Montecucco C, Schiavo G (1995) Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 28: 423-472. (Pubitemid 26015975)
3. Boldt GE, Kennedy JP, Janda KD (2006) Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett 8: 1729-1732. (Pubitemid 43691125)
4. Zuniga JE, Schmidt JJ, Fenn T, Burnett JC, Arac D, et al. (2008) A Potent Peptidomimetic Inhibitor of Botulinum Neurotoxin Serotype A Has a Very Different Conformation than SNAP-25 Substrate. Structure 16: 1588-1597.
5. Molles BE, Collins EK, Levit MB, Sweeny RE, Zottola MA, et al. (2010) Towards a sub-nanomolar affinity BoNT/A light chain protease inhibitor: clues from structure-activity studies of peptide inhibitors. In: Maslanka SE, editor. 47th Inter-institute Botulinum Research Coordinating Committee Meeting. Atlanta, GA: CDC.
6. Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery: A guide to chemists and pharmacologists. Hoboken, New Jersey, USA: Wiley-Interscience. 271 p.
7. Simpson LL (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44: 167-193.
8. Schmidt JJ, Stafford RG (2005) Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry 44: 4067-4073. (Pubitemid 40358059)
9. Schmidt JJ, Stafford RG (2002) A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett 532: 423-426. (Pubitemid 35441386)
10. Schmidt JJ, Stafford RG, Bostian KA (1998) Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S19 binding subsite. FEBS Lett 435: 61-64. (Pubitemid 28432015)
11. Kumar G, Kumaran D, Ahmed SA, Swaminathan S (2012) Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling. Acta Crystallogr D Biol Crystallogr 68: 511-520.
12. Hale M, Oyler G, Swaminathan S, Ahmed SA (2011) Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J Biol Chem 286: 1802-1811.
13. Ludivico M, Smith LA, Ahmed SA (2009) Structure-Based Design of Peptide Inhibitors of Botulinum Neurotoxin Serotypes A Proteolytic Activity. The Botulinum Journal 1: 297-308.
14. Kumaran D, Rawat R, Ludivico ML, Ahmed SA, Swaminathan S (2008) Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A. J Biol Chem 283: 18883-18891.
15. Kumaran D, Rawat R, Ahmed SA, Swaminathan S (2008) Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog4: e1000165.
16. Roxas-Duncan V, Enyedy I, Montgomery VA, Eccard VS, Carrington MA, et al. (2009) Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother 53: 3478-3486.
17. Hermone AR, Burnett JC, Nuss JE, Tressler LE, Nguyen TL, et al. (2008) Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. ChemMedChem 3: 1905-1912.
18. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, et al. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A 104: 2602-2607. (Pubitemid 46327926)
19. Dickerson TJ, Janda KD (2007) The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem Biol 2: 359-369.
20. Capkova K, Yoneda Y, Dickerson TJ, Janda KD (2007) Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. Bioorg Med Chem Lett 17: 6463-6466. (Pubitemid 350026341)
21. Ma H, Zhou B, Kim Y, Janda KD (2006) A cyclic peptide-polymer probe for the detection of Clostridium botulinum neurotoxin serotype A. Toxicon 47: 901-908. (Pubitemid 43849896)
22. Mizanur RM, Gorbet J, Swaminathan S, Ahmed SA (2012) Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium. Int J Biochem Mol Biol 3: 313-321.
23. Ahmed SA (2013) Recent advances in the botulinum neurotoxin catalytic activity assays. In: Pandalai SG, editor. Recent Research Developments in Analytical Biochemistry. 1st ed. Trivandrum, Kerala, India: Transworld Research Network. pp. 43.
24. Mizanur RM, Frasca V, Swaminathan S, Bavari S, Webb R, et al. (2013) The C terminus of the catalytic domain of type a botulinum neurotoxin may facilitate product release from the active site. J Biol Chem 288: 24223-24233.
25. Gul N, Smith LA, Ahmed SA (2010) Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form. PLoS ONE 5: e12872.
26. Schmidt JJ, Stafford RG (2003) Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol69: 297-303. (Pubitemid 36077488)
27. Rowe B, Schmidt JJ, Smith LA, Ahmed SA (2010) Rapid product analysis and increased sensitivity for quantitative determinations of botulinum neurotoxin proteolytic activity. Anal Biochem 396: 188-193.
28. Ahmed SA, Olson MA, Ludivico ML, Gilsdorf J, Smith LA (2008) Identification of Residues Surrounding the Active Site of Type A Botulinum Neurotoxin Important for Substrate Recognition and Catalytic Activity. Protein J 27: 151-162. (Pubitemid 351652551)
29. Henkel JS, Jacobson M, Tepp W, Pier C, Johnson EA, et al. (2009) Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 48: 2522-2528.
30. Chen S, Barbieri JT (2006) Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem 281: 10906-10911. (Pubitemid 43855514)
31. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432: 925-929. (Pubitemid 40037157)
32. Cai S, Lindo P, Park JB, Vasa K, Singh BR (2010) The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity. Toxicon 55: 818-826.
33. (2012) LIST Biological Laboratories Inc. Available: http://www.listlabs. com/.
34. Ahmed SA, Smith LA (2000) Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active. J Protein Chem 19: 475-487. (Pubitemid 32043069)
35. Schmidt JJ, Bostian KA (1997) Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J Protein Chem 16: 19-26. (Pubitemid 27114001)
36. Shone CC, Roberts AK (1994) Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin. Eur J Biochem 225: 263-270. (Pubitemid 24306251)
37. Auld DS (1995) Removal and replacement of metal ions in metallopeptidases. Methods Enzymol 248: 228-242.
38. Jensen MJ, Smith TJ, Ahmed SA, Smith LA (2003) Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 41: 691-701. (Pubitemid 36515008)
39. Ekong TA, Feavers IM, Sesardic D (1997) Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143 (Pt 10): 3337-3347. (Pubitemid 27470183)
40. Sadoul K, Berger A, Niemann H, Regazzi R, Catsicas S, et al. (1997) SNAP-25 can self-associate to form a disulfide-linked complex. Biol Chem 378: 1171-1176. (Pubitemid 27474664)
41. Glass PJ, Zeng CQ, Estes MK (2003) Two nonoverlapping domains on the Norwalk virus open reading frame 3 (ORF3) protein are involved in the formation of the phosphorylated 35K protein and in ORF3-capsid protein interactions. J Virol 77: 3569-3577. (Pubitemid 36297276)
42. Creighton TE (1984) Proteins Structures and Molecular Properties. New York: W.H. Freeman and Company. 515 p.
43. Ahmed SA, Olson MA, Ludivico ML, Gilsdorf J, Smith LA (2008) Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity. Protein J 27: 151-162. (Pubitemid 351652551)
44. Schmidt JJ, Bostian KA (1995) Proteolysis of synthetic peptides by type A botulinum neurotoxin. J Protein Chem 14: 703-708. (Pubitemid 26006119)
45. Toth S, Brueggmann EE, Oyler GA, Smith LA, Hines HB, et al. (2012) Tyrosine phosphorylation of botulinum neurotoxin protease domains. Front Pharmacol 3: 102.
46. Toth SI, Smith LA, Ahmed SA (2009) Extreme sensitivity of botulinum neurotoxin domains towards mild agitation. J Pharm Sci 98: 3302-3311.
47. Foran P, Lawrence G, Dolly JO (1995) Blockade by botulinum neurotoxin B of catecholamine release from adrenochromaffin cells correlates with its cleavage of synaptobrevin and a homologue present on the granules. Biochemistry 34: 5494-5503.
48. Ahmed SA, McPhie P, Smith LA (2003) Autocatalytically fragmented light chain of botulinum a neurotoxin is enzymatically active. Biochemistry 42: 12539-12549. (Pubitemid 37337544)
49. Gilsdorf J, Gul N, Smith LA (2006) Expression, purification, and characterization of Clostridium botulinum type B light chain. Protein Expr Purif 46: 256-267.
50. Hatheway CL (1988) Botulism. In: (eds), vol 1., New York, In:Balows A, W.H.J. H, M. O, A. T, editors. Laboratory Diagnosis of Infectious Diseases: Principles and Practice. New York: Springer. pp. 112-133.
51. Li L, Singh BR (2000) Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure. Biochemistry 39: 10581-10586. (Pubitemid 30655936)
52. Baldwin MR, Bradshaw M, Johnson EA, Barbieri JT (2004) The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr Purif 37: 187-195. (Pubitemid 39027259)
53. Binz T, Bade S, Rummel A, Kollewe A, Alves J (2002) Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 41: 1717-1723. (Pubitemid 34132245)
54. Cai S, Singh BR (2001) A correlation between differential structural features and the degree of endopeptidase activity of type A botulinum neurotoxin in aqueous solution. Biochemistry 40: 4693-4702. (Pubitemid 32374658)
55. Sharma SK, Singh BR (2004) Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 43: 4791-4798. (Pubitemid 38509100)
56. Adler M, Capacio B, Deshpande SS (2000) Antagonism of botulinum toxin Amediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps. Toxicon 38: 1381-1388. (Pubitemid 30176108)
57. Bagramyan K, Barash JR, Arnon SS, Kalkum M (2008) Attomolar detection of botulinum toxin type A in complex biological matrices. PLoS One 3: e2041.
58. Rasooly R, Do PM (2008) Development of an in vitro activity assay as an alternative to the mouse bioassay for Clostridium botulinum neurotoxin type A. Appl Environ Microbiol 74: 4309-4313. (Pubitemid 352031011)
59. Ruge DR, Dunning FM, Piazza TM, Molles BE, Adler M, et al. (2011) Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Anal Biochem 411: 200-209.